Know Cancer

or
forgot password

Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES


N/A
18 Years
N/A
Open (Enrolling)
Both
Myelodysplastic Syndrome

Thank you

Trial Information

Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES


Inclusion Criteria:



- Written informed consent

- Patients diagnosed with MDS according to FAB, WHO and IPSS classifications

- All clinically treatable MDS patients with EPO or Lenalidomide or 5-Azacytidine;

- Hb < 10 g/dL

- Age ≥ 18 years

- Gender: Male or Female

- Sufficient amount of biological samples for molecular studies

Exclusion Criteria:

- Age <18 years

- Patients who do not require treatment on "watch and wait" strategy

- Insufficient amount of biological samples for molecular studies

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Analyze the incidence of TET2 gene mutations and Validation of the prognostic potential of TET2 mutations and MPLA screening

Outcome Description:

Analyze the incidence of TET2 gene mutations in a series of MDS patients and describe the clinical status of patients carrying mutations Validation of the prognostic potential of TET2 mutations and MPLA screening on: Response rate to treatment with Epo, Lenalidomide and Azacitidine Progression Free Survival (PFS )

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Fortunato Morabito, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Unità Operativa Complessa di Ematologia- Azienda Ospedaliera di Cosenza - Italy

Authority:

Italy: Ethics Committee

Study ID:

O-MDS-PROTOCOL

NCT ID:

NCT01291745

Start Date:

September 2010

Completion Date:

September 2015

Related Keywords:

  • Myelodysplastic Syndrome
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location